[{"from": "human", "value": "What can you tell me about this molecule? [C][C][N][Branch1][Ring1][C][C][C][C][N][C][=Branch1][C][=O][C][=C][Branch2][Ring1][=N][N][C][=Branch1][Branch1][=C][Ring1][Branch1][C][/C][=C][/C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][N][C][\\-Ring1][#Branch2][=O][C].[C][Branch1][#Branch2][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][O][C][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells."}]